Johanna Rossell, Enzyvant chief commercial officer

A se­nior Bio­gen com­mer­cial ex­ec ex­its Alzheimer's unit amid ex­o­dus as Aduhelm woes mount

One of Bio­gen’s se­nior com­mer­cial ex­ecs on the Alzheimer’s side of the busi­ness is ex­it­ing the trou­bled com­pa­ny af­ter a se­ries of set­backs suf­fered dur­ing a failed at­tempt to launch their con­tro­ver­sial drug Aduhelm.

Jo­han­na Rossell, a No­var­tis com­mer­cial vet who had been Bio­gen’s glob­al com­mer­cial lead for the Alzheimer’s busi­ness unit, com­plet­ed her last day of work at Bio­gen yes­ter­day, ac­cord­ing to a com­pa­ny spokesper­son. En­zy­vant — a Roivant start­up ac­quired by Sum­it­o­mo Dainip­pon — an­nounced that she had joined them as their new com­mer­cial chief ear­li­er to­day. She’s one of 3 No­var­tis vets that just land­ed new roles run­ning com­mer­cial ops in biotech.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.